Stargardt
Conditions
Keywords
ZVS106e
Brief summary
To evaluate the preliminary safety of monocular and single subretinal injection of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations.
Detailed description
The main research objective: To evaluate the preliminary safety of single subretinal injection of ZVS106e injection in one eye for patients with hereditary retinal degeneration (ABCA4-IRDS) caused by biallelic mutations in ABCA4. Secondary research objective: To preliminarily explore the clinical efficacy of ZVS106e injection in the treatment of patients with hereditary retinal degeneration (ABCA4-IRDS) caused by ABCA4 biallelic mutations. The purpose of the exploratory study is to evaluate the improvement of retinal structure and visual function in non-injection eyes compared to the baseline.
Interventions
DRUGZVS106e
ZVS106e is A colorless, clear and transparent liquid, containing two active ingredients, ZVS106E-A and ZVS106E-B. The viral vectors used for both active ingredients are rAAV8
Sponsors
Zhongshan Ophthalmic Center, Sun Yat-sen University
Chigenovo Co., Ltd
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
8 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥8 years old; 2. Patients diagnosed with hereditary retinal degeneration caused by ABCA4 biallelic mutations through genetic testing, and without other ophthalmic genetic diseases; 3. The target eye must meet the following requirements: the best corrected visual acuity is 0.5 to 2.0 LogMAR (including 0.5 and 2.0 LogMAR, equivalent to the decimal visual acuity index up to 0.3); 4. The subject and his or her spouse agree to take effective contraceptive measures during the trial period and for at least one year after administration. 5. Voluntarily participate in clinical trials and sign informed consent forms, and be able to complete all trial processes as required by the protocol.
Exclusion criteria
1. The researchers determined that the target eye currently has or has previously had other macular lesions such as retinal schisis or epiretinal membrane. Or have other eye diseases that may hinder the surgery or interfere with the interpretation of the study endpoint; 2. Having received drug treatment that may affect the observation of the trial within the three months prior to screening; 3. The target eye has undergone the following intraocular surgeries: retinal repositioning and vitrectomy; 4. There are known eye/visual diseases, disorders or lesions that cause or are related to vision loss, or whose related treatments or therapies are known to cause or are related to vision loss; 5. Having suffered from a viral infectious disease that may affect the efficacy and safety evaluation of the investigational drug or having received an antiviral vaccine within one month prior to enrollment; 6. Systemic medications that are currently in use or may be required to cause eye toxicity, such as psoralen, risselinic acid or tamoxifen, etc. 7. Known to be allergic to the drugs planned to be used in the study; 8. Suffering from poorly drug-controlled hypertension: systolic blood pressure ≥160 mmHg or diastolic blood pressure ≥100 mmHg; 9. The following laboratory test abnormalities have clinical significance: Liver function: Chronic liver disease, elevation of ALT or AST \>2 times the upper limit of the normal value; Those with abnormal coagulation function (prothrombin time ≥ 3 seconds above the upper limit of the normal value, activated partial thromboplastin time ≥ 10 seconds above the upper limit of the normal value); Serum virological examination: Positive for active hepatitis B, hepatitis C virus antibody (HCV-Ab), human immunodeficiency virus antibody (HIV-Ab), or syphilis antibody; 10. There is any past or current medical history that may affect the safety of the trial or the in vivo process of the drug, especially a history of diseases such as cardiovascular, liver, kidney, endocrine, digestive tract, lung, nervous, hematological, tumor, immune or metabolic disorders that the investigators consider to have clinical significance; 11. Those who have participated in any clinical trials of drugs or medical devices within the three months prior to screening; 12. Pregnant or lactating women; According to the researcher's judgment, those who are deemed unsuitable to participate in this clinical trial for other reasons
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Evaluate the safety and tolerability of subretinal injection of ZVS106e solution | 52 weeks post-treatment | Types, severity, and incidence of adverse events (AE) and serious adverse events (SAE) in the eyes and throughout the body within 52 weeks post-treatment, including dose-limiting toxicities (DLT) during the dose escalation phase. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change from baseline in best-corrected visual acuity (BCVA) | 52 weeks post-treatment | Change in best-corrected visual acuity (BCVA) of the treated eye at 52 weeks compared to baseline. |
| Change from Baseline in Visual function metrics | 52 weeks post-treatment | Treatment outcomes for visual function metrics include changes from baseline in LLVA, dynamic visual field, microperimetry, FST, contrast sensitivity, color vision, and mfERG; as well as changes from baseline in the NEI-VFQ-25 score reported by the participants. |
| Change from Baseline in OCT | 52 weeks post-treatment | Compare changes in retinal morphology and alterations in cell layers of the retina before and after drug administration. |
| Change from Baseline in Fundus autofluorescence (FAF) | 52 weeks post-treatment | Compare the atrophy of the RPE/ photoreceptor complex in the subjects before and after administration |
Countries
China
Contacts
CONTACTdayou Ding
STUDY_DIRECTORqingjiong zhang, M.D
PI
PRINCIPAL_INVESTIGATORlin Lv, M.D
PI
Outcome results
None listed